RVTY.NYSERevvity, INC

DEF: Revvity, Inc. Announces 2025 Annual Shareholder Meeting and Proxy Statement

Sentiment:

Proxy Statement


Revvity, Inc. has released its proxy statement for the 2025 annual shareholder meeting, detailing proposals for director elections, auditor ratification, executive compensation, and governance amendments.

Delay expectedIn February 2024, the committee approved a delay of the effective date of the approved base pay increases in an effect to control costs given uncertain and challenges conditions in the life sciences industry.In August 2024, the committee approved moving forward with the approved merit increases effective September 2, 2024.
Better than expectedThe company's GAAP earnings per share from continuing operations increased from $1.44 in 2023 to $2.30 in 2024.Adjusted earnings per share from continuing operations increased from $4.65 in 2023 to $4.90 in 2024.GAAP operating income from continuing operations increased from $301 million in 2023 to $347 million in 2024.GAAP operating profit margin from continuing operations increased from 10.9% in 2023 to 12.6% in 2024.

Summary

  • Revvity, Inc. will hold its 2025 annual meeting of shareholders virtually on April 22, 2025, at 8:00 a.m. Eastern Time.
  • Shareholders of record as of February 25, 2025, are entitled to vote on several proposals.
  • The proposals include the election of ten directors, ratification of Deloitte & Touche LLP as the independent auditor, an advisory vote on executive compensation, and amendments to the company's governance documents.
  • A shareholder proposal regarding the ability to call a special shareholder meeting will also be considered.
  • The board of directors recommends voting for the election of directors, ratification of the auditor, approval of executive compensation, and the governance amendments, but against the shareholder proposal.
  • The company overcame industrywide headwinds throughout 2024, leading to top quartile and differentiated financial results for the year.
  • GAAP earnings per share from continuing operations were $2.30 for fiscal year 2024, compared to $1.44 for fiscal year 2023.
  • Adjusted earnings per share from continuing operations for fiscal year 2024 was $4.90, compared to $4.65 in fiscal year 2023.
  • GAAP revenue for fiscal year 2024 was $2,755 million, compared to $2,751 million in fiscal year 2023.
  • GAAP operating income from continuing operations for fiscal year 2024 was $347 million, compared to $301 million in fiscal year 2023.
  • GAAP operating profit margin from continuing operations was 12.6% for fiscal year 2024, compared to 10.9% for fiscal year 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with improved financial performance and strategic initiatives, although there are some governance concerns regarding shareholder proposals.

Positives

  • The company's GAAP earnings per share from continuing operations increased from $1.44 in 2023 to $2.30 in 2024.
  • Adjusted earnings per share from continuing operations increased from $4.65 in 2023 to $4.90 in 2024.
  • GAAP revenue increased slightly from $2,751 million in 2023 to $2,755 million in 2024.
  • GAAP operating income from continuing operations increased from $301 million in 2023 to $347 million in 2024.
  • GAAP operating profit margin from continuing operations increased from 10.9% in 2023 to 12.6% in 2024.
  • The board is recommending to remove supermajority voting requirements.

Negatives

  • A shareholder proposal seeks to lower the threshold for calling a special shareholder meeting to 10% ownership, which the board opposes.
  • The board believes such a low ownership threshold creates the risk that a very small number of shareholders may use this procedure to act unilaterally or to advance their own interests at the expense of other shareholders.

Risks

  • The board opposes the shareholder proposal to lower the threshold for calling a special shareholder meeting, citing potential harm to minority shareholders and waste of company resources.
  • The board believes such a low ownership threshold creates the risk that a very small number of shareholders may use this procedure to act unilaterally or to advance their own interests at the expense of other shareholders.

Future Outlook

The company believes that its range of product offerings, leading market positions, global scale, financial strength, and strong culture, provide it with a foundation for continued long-term growth, margin expansion and robust cash flow generation.

Management Comments

  • Our performance in the face of an evolving macro environment is both a testament to the hard work of our incredible team and the result of the transformation that has taken place at our Company in recent years, not only from a portfolio composition standpoint, but also from an operational agility and collaboration perspective.

Industry Context

The document highlights Revvity's performance amidst industry-wide headwinds, suggesting a resilient business model compared to competitors facing similar challenges.

Comparison to Industry Standards

  • The document states that Revvity overcame industrywide headwinds throughout 2024, leading to top quartile and differentiated financial results for the year.
  • The document does not provide specific comparisons to individual companies, but it does mention a peer group of companies used for pay comparisons and evaluating relative performance, including Agilent Technologies, Bruker Corporation, Hologic, Inc., Thermo Fisher Scientific Inc., and Danaher Corporation.
  • The document also mentions a relative TSR peer group of 31 companies used in the 2024 LTIP program, including 10X Genomics, Inc., Illumina, Inc., and QIAGEN N.V.

Corporate Governance

Change TypeDescriptionEffective DateImpact Assessment
Proposed AmendmentAmendments to Restated Articles of Organization and Amended and Restated By-laws to implement a majority voting standard for specified corporate actions.Upon shareholder approval and filing of Articles of Amendment.Would replace supermajority voting requirements with a requirement that such matters be approved by a majority of shares outstanding and entitled to vote.

Stakeholder Impact

  • Shareholders are impacted by the proposals to be voted on at the annual meeting, including director elections, executive compensation, and governance amendments.
  • Employees are impacted by the company's compensation and benefits programs, as well as the company's commitment to talent development and professional growth.
  • Customers are impacted by the company's commitment to innovation and the development of new products and services.
  • The company's performance and strategic initiatives impact all stakeholders, including shareholders, employees, customers, and suppliers.

Next Steps

  • Shareholders are encouraged to review the proxy materials and vote on the proposals.
  • The board of directors will review the voting results and consider any necessary actions.

Key Dates

DateDescription
2025-02-25Record date for determining shareholders entitled to vote at the annual meeting.
2025-03-12Approximate date on which the proxy statement and form of proxy were first sent to shareholders.
2025-04-22Date of the annual meeting of shareholders.
2025-11-12Deadline for shareholder proposals to be considered for addition to the agenda for the 2026 annual meeting.
2025-11-23Earliest date for notice of proxy access nomination for the 2026 annual meeting.
2025-12-23Latest date for notice of proxy access nomination for the 2026 annual meeting.
2026-02-06Deadline for shareholders to send notice to Revvity to nominate a director for election at the 2026 annual meeting.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.